Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 6/20 | 0.40 |
| ▸ | MAOA | P21397 | 4/20 | 0.40 |
| ▸ | AR | P10275 | 3/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | ESRRA | P11474 | 3/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10088902 | 0.90 | MAOB (0.42) | SLC6A4SRD5A1MAOBMAOAAR | |
| SCHEMBL10088460 | 0.89 | MAOB (0.38) | SRD5A1MAOBMAOAAR | |
| SCHEMBL10088922 | 0.88 | SRD5A1 (0.47) | SLC6A4SRD5A1MAOBMAOASRD5A2 | |
| SCHEMBL10089035 | 0.85 | MAOB (0.41) | SLC6A4SRD5A1MAOBMAOASRD5A2 | |
| SCHEMBL10088929 | 0.81 | SRD5A1 (0.47) | SLC6A4SRD5A1MAOBMAOASRD5A2 | |
| SCHEMBL12441109 | 0.81 | SRD5A1 (0.37) | SLC6A4SRD5A1MAOBMAOASRD5A2 | |
| SCHEMBL10088464 | 0.80 | MAOB (0.45) | SRD5A1MAOBMAOAAR | |
| SCHEMBL10088527 | 0.79 | MAOB (0.39) | SRD5A1MAOBMAOAAR | |
| SCHEMBL2326732 | 0.78 | SRD5A1 (0.42) | SLC6A4SRD5A1MAOBMAOAAR | |
| SCHEMBL10089020 | 0.78 | S1PR1 (0.53) | PIM1PDGFRAS1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| WO-2010064707-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | アステラス製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | SLC6A4 2336/4885SRD5A1 397/4885MAOB 2521/4885 |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | SLC6A4 2561/4885SRD5A1 494/4885MAOB 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.